Even the highest-risk apps, based on patient condition and significance of information, would be allowed to take advantage of a streamlined review process for companies vetted under US FDA's oncoming pre-certification program under an initial outline of the program. And many lower-risk apps would see no review to reach market. That's according to the agency's newly posted "working model" for the pre-cert program, which the agency plans to launch in its first iteration by the end of the year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?